---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-075865"
form_type: "8-K"
ticker: "XAGE"
cik: "0001842939"
company_name: "Longevity Health Holdings, Inc."
filed_at: "2025-05-21T23:59:59+00:00"
generated_at: "2026-05-20T22:44:36.374510+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nasdaq panel grants conditional continued listing for Longevity Health pending merger with 20/20 Biolabs by Sept 2, 2025

## Summary
- Nasdaq Hearings Panel granted continued listing condition: complete merger with 20/20 Biolabs and meet initial listing rules by Sept 2, 2025.
- Company filed S-4 for merger on May 8, 2025, and effected 1-for-30 reverse stock split on May 12, 2025.
- Panel based decision on review of financial statements and pro forma projections of combined company.
- Chairman/CEO Rajiv Shukla stated focus on completing merger to satisfy Nasdaq requirements.

## SEC filing metadata
- accession: 0000950170-25-075865
- form_type: 8-K
- ticker: XAGE
- cik: 0001842939
- company_name: Longevity Health Holdings, Inc.
- filed_at: 2025-05-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842939/000095017025075865/0000950170-25-075865-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842939/000095017025075865/xage-20250520.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-075865
- JSON: https://secwatch.observer/filing/0000950170-25-075865.json
- Plain text: https://secwatch.observer/filing/0000950170-25-075865.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.